Earnings Summary

Halozyme Therapeutics, Inc.’s revenue fell -68.23% since last year same period to $60.23Mn in the Q4 2018. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 135.69% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit fell -101.72% since last year same period to $-2.13Mn in the Q4 2018. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 92.37% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin fell -105.4% since last year same period to -3.53% in the Q4 2018. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 96.76% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.47 - a -7.84% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.47.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 34.55% since last year same period to 0.74 in the Q3 2022. This indicates that the Halozyme Therapeutics, Inc. has generated 34.55% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.11.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.12.